Zacks.com on MSN23h
Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down
Alkermes plc ALKS reported adjusted earnings from continuing operations of 73 cents per share for third-quarter 2024, which ...
Alkermes: Strong Buy Rating Amidst Short-term Challenges and Long-term Growth Potential
Robert W. Baird analyst Joel Beatty maintained a Buy rating on Alkermes (ALKS – Research Report) yesterday and set a price target of ...
Alkermes' Q3 Proprietary Sales Soar 18%
The biopharma company's third-quarter report highlighted robust proprietary product performance, despite some weakness ...
Alkermes: Navigating Revenue Shifts and Investing in Orexin-2 Agonist Amidst Neutral Profit Outlook
Analyst Douglas Tsao from H.C. Wainwright reiterated a Hold rating on Alkermes (ALKS – Research Report) and keeping the price target at ...
Investor's Business Daily on MSN11d
Alkermes Stock Jumps Nearly 30% In 3 Months After Hefty Profits
Drugmaker Alkermes put up some astounding growth numbers and its stock rose sharply as a result. Until last quarter that is.
Alkermes Third Quarter 2024 Earnings: EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 2.9%. Looking ahead, revenue ...
ETF Daily News7d
FY2024 EPS Estimates for Alkermes Lowered by Leerink Partnrs
Alkermes plc (NASDAQ:ALKS – Free Report) – Stock analysts at Leerink Partnrs dropped their FY2024 earnings per share ...
Alkermes: Q3 Earnings Snapshot
DUBLIN (AP) — DUBLIN (AP) — Alkermes PLC (ALKS) on Thursday reported third-quarter profit of $92.4 million. On a per-share basis, the Dublin-based company said it had profit of 55 cents. Earnings, ...
Alkermes PLC (ALKS) Q3 2024 Earnings Report Preview: What to Expect
Alkermes PLC (NASDAQ:ALKS) is set to release its Q3 2024 earnings on Oct 24, 2024. The consensus estimate for Q3 2024 revenue ...
PR Newswire2d
Alkermes plc Reports Third Quarter 2024 Financial Results
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Thursday, ...
高盛维持Alkermes股票买入评级，但在里程碑数据公布前下调目标价
周五，高盛下调了Alkermes Plc (NASDAQ:ALKS)的目标价，从之前的32.00美元降至30.00美元，但仍然维持买入评级。分析师表示，这一调整是基于公司2024年第三季度的表现，该表现与当前商业产品组合的预期一致。 季度报告揭示了管理层评论中的一些关键点。其中之一是初步指引暗示公司从2025年开始财务状况将发生重塑。这一转变预计是由于传统制造业务特许权使用费的预期下降，以及对Ly ...
Piper Sandler下调Alkermes股票目标价，维持增持评级
周五，Piper Sandler将生物制药公司Alkermes (NASDAQ:ALKS)的股票目标价从之前的38.00美元下调至37.00美元。在该公司最新财报公布后，该机构维持了对该股票的增持评级。 Alkermes报告其2024财年第三季度非GAAP每股收益(EPS)为0.72美元，略高于预期的0.70美元，收入为3.781亿美元，略低于预期的3.809亿美元。尽管业绩喜忧参半，但公司管理层 ...